Table 2.
Metabolite | a VIP | bp Value | c FDR | d FC |
---|---|---|---|---|
DAG (16:0/18:2) | 2.099 | <0.001 | <0.001 | 1.520 |
LPC 20:3(SN2) | 1.573 | 0.001 | <0.001 | 1.266 |
PC (16:0e/26:4) | 3.123 | <0.001 | <0.001 | 0.635 |
PC (16:1e/18:2) | 1.559 | <0.001 | <0.001 | 0.743 |
PC (18:1/18:2.1) | 1.805 | <0.001 | 0.001 | 0.814 |
PC (18:1/22:6) | 1.924 | <0.001 | 0.001 | 0.759 |
PC (18:1e/18:2) | 2.693 | <0.001 | <0.001 | 0.745 |
PC (20:4e/26:4) | 1.889 | <0.001 | <0.001 | 0.666 |
PE (16:0e/22:6) | 1.589 | <0.001 | 0.001 | 0.856 |
TAG (16:0/18:1/22:5) | 2.425 | <0.001 | <0.001 | 1.426 |
TAG (16:0/18:2/20:4) | 1.783 | <0.001 | <0.001 | 1.494 |
TAG (16:0/20:4/22:6) | 1.864 | <0.001 | <0.001 | 1.475 |
TAG (18:0/18:1/18:1) | 2.065 | <0.001 | <0.001 | 1.456 |
TAG (18:0/18:1/20:4) | 3.104 | <0.001 | <0.001 | 1.726 |
TAG (18:1/18:2/22:5) | 2.684 | <0.001 | <0.001 | 1.548 |
a VIP was obtained from the OPLS-DA model with a threshold of 1.0. b p Values were obtained from one-way ANOVA. The value of c FDR was obtained from the adjusted p Value in the metaboanalyst 5.0 software. The value of d FC was obtained by comparing those metabolites in patients with AS with the HCs. VIP: variable importance in the projection, FC: fold change, and FDR: false discovery rate.